Pacritinib for the Treatment of Patients with Myelofibrosis

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen Oh, MD, discussed treatment options for steroid-refractory high-risk primary myelofibrosis based on the patient's platelet count.

Gary J. Schiller, MD, discusses the treatment for blastic plasmacytoid dendritic cell neoplasm and what clinicians need to look out for when evaluating these rare occurrences.

The combination of CDK9 plus BTK inhibition has already demonstrated synergistic clinical efficacy vs BTK inhibition alone. Now, a clinical trial collaboration will evaluate PRT2527 and zanubrutinib for patients with hematologic malignancies.

Results were published from a phase 1b trial of patients with higher-risk myelodysplastic syndromes, showing strong efficacy and safety outcomes.

During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed 3 recommended agents for treatment of chronic graft-vs-host disease. This is the second of 2 articles based on this event.